Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Federal contracts (SAM.gov)The Ultimate Guide to SAM.gov Registration
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to answer an RFPChoosing and Responding to Government Bids
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Federal
  4. ›GENETIC MEDICINES AND INDIVIDUALIZED MANUFACTURING FOR…

U.S. Department Of Health And Human Services·District of Columbia

GENETIC MEDICINES AND INDIVIDUALIZED MANUFACTURING FOR EVERYONE (GIVE)

Closes 2/27/2026$10M – $50MRequest for Proposal
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals for the Genetic Medicines And Individualized Manufacturing For Everyone (GIVE) program. The program aims to accelerate biomanufacturing equipment and process innovation, digital transformation, next-generation therapies, and commercial adoption. The goal is to enable the manufacturing of genetic medicines, such as RNA-based therapies, in a distributed and individualized manner, reducing costs and increasing accessibility. Proposers are expected to submit solution summaries and full proposals, which will be evaluated based on technical merit, proposer capabilities, and potential contribution to the ARPA-H mission. The program consists of three phases, with multiple awards anticipated, and a total duration of 54 months. • The program has two technical areas: Automated RNA Manufacturing and Integrated Quality Control. • Proposers can submit to one or both technical areas. • The program aims to develop a distributed manufacturing ecosystem for genetic medicines. • Proposers are expected to provide detailed engineering and software architecture designs, as well as product demonstrations. • The program has a strong focus on intellectual property, research security, and compliance with federal regulations.

Attached files

Contact

[email protected]

Key dates

Opened
9/25/2025
Questions due
2/13/2026
Pre-bid meeting
11/13/2025
Closes
2/27/2026
Duration
54 months

Last updated

Details

Type
Request for Proposal
Industry
Healthcare and Medical Services
NAICS
541714
Solicitation №
ARPA-H-SOL-25-129

Budget estimate

$10,000,000 – $50,000,000

The budget for this opportunity is likely to be substantial, given the program's focus on biomanufacturing innovation and genetic medicine development. The exact budget amount is not specified, but based on the program's goals and scope, it is estimated to be in the range of $10 million to $50 million. The budget will depend on the proposer's ability to develop and demonstrate a distributed manufacturing system for genetic medicines, as well as their ability to meet the program's technical and regulatory requirements. Factors that may influence the budget range include the complexity of the proposed solution, the level of innovation and risk involved, and the proposer's experience and track record in biomanufacturing and genetic medicine development.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 66%

Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)

Closes 12/14/2026Opened 5/12/2025

U.S. Food and Drug Administration·United States of America

64% match

Novel approaches to support therapeutic development in ultra-rare cancers

Rolling / TBD closeOpened 8/4/2025

U.S. Department Of Defense·Maryland

64% match

Notice of Intent DNA Synthesizer

Closes 11/2/2026Opened 10/15/2026

U.S. Food and Drug Administration·United States of America

64% match

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)

Rolling / TBD closeOpened 7/11/2025

U.S. National Institutes of Health·United States of America

63% match

Somatic Mosaicism across Human Tissues (SMaHT) Program: National Somatic Mosaicism Commons Data Analysis & Organizational Center (UM1 Clinical Trial Not Allowed)

Closes 6/30/2027Opened 9/14/2026

U.S. Department Of Energy·Ohio

63% match

TECHNOLOGY LICENSING OPPORTUNITY: NanoFET

Closes 12/17/2026Opened 6/17/2026

U.S. National Institutes of Health·United States of America

63% match

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

63% match

INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)

Closes 6/15/2028Opened 9/25/2025

U.S. National Institutes of Health·United States of America

63% match

Somatic Mosaicism across Human Tissues (SMaHT) Program: Experimental and Computational Technology Development (RM1 Clinical Trial Not Allowed)

Closes 6/30/2027Opened 9/14/2026

U.S. National Institutes of Health·United States of America

63% match

A Holistic Approach to Study Non-Addictive Natural Products for Pain Management

Closes 5/24/2027Opened 4/22/2026

U.S. National Institutes of Health·United States of America

63% match

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

Closes 3/1/2027Opened 1/8/2026

U.S. National Institutes of Health·United States of America

63% match

ancient DNA for Modern Genomics (aDMG) Research Projects (U01 Clinical Trials Not Allowed)

Closes 1/31/2028Opened 6/2/2026

U.S. National Institutes of Health·United States of America

63% match

INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed)

Closes 6/14/2027Opened 7/28/2026

U.S. Food and Drug Administration·United States of America

63% match

Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)

Rolling / TBD closeOpened 7/11/2025

U.S. Department Of Health And Human Services·Maryland

63% match

RNA sequencing and whole genome sequencing services

Closes 11/6/2026Opened 10/28/2026

U.S. National Institutes of Health·United States of America

63% match

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)

Closes 6/15/2027Opened 9/25/2024

U.S. National Institutes of Health·United States of America

62% match

Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)

Closes 9/28/2028Opened 6/9/2025

U.S. National Institutes of Health·United States of America

62% match

Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed)

Closes 1/8/2027Opened 5/14/2025

U.S. National Institutes of Health·United States of America

62% match

Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

62% match

Digital Health Technology and Reciprocal Innovation to Improve Clinical and Public Health Outcomes

Closes 2/10/2027Opened 7/2/2026

U.S. National Institutes of Health·United States of America

62% match

Somatic Mosaicism across Human Tissues (SMaHT) Program: Genome Characterization Centers (UM1 Clinical Trial Not Allowed)

Closes 6/30/2027Opened 9/14/2026

U.S. National Institutes of Health·United States of America

62% match

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

Closes 12/23/2027Opened 11/22/2024

U.S. National Institutes of Health·United States of America

62% match

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

Closes 10/8/2027Opened 12/18/2024

U.S. Department Of Energy·Ohio

62% match

TECHNOLOGY LICENSING OPPORTUNITY: SignalGen

Closes 3/22/2027Opened 9/22/2026

U.S. Food and Drug Administration·United States of America

62% match

Center for Research on Complex Generics (U18) Clinical Trials Optional

Rolling / TBD closeOpened 8/14/2024